Racura Oncology Ltd
Racura Oncology Ltd is a biotechnology company focused on pharmaceuticals and medical research.
Business. Racura Oncology Ltd (RAC.AX) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Australian Securities Exchange (ASX). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Racura Oncology Ltd (RAC.AX) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Australian Securities Exchange (ASX). Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.
Racura Oncology Ltd has an undetermined liquidity position, as no balance-sheet inputs are available and no going-concern language is present in the source documents. The company's valuation snapshot is not available, and no liquidity risk assessment can be made at this time.
The company's profitability and returns cannot be assessed due to the absence of financial metrics and industry benchmarks. No data is available to compare against the preferred metrics for the Biotechnology & Medical Research industry.
Segment and geographic exposure details are not disclosed in the available data. The company's revenue concentration and geographic distribution remain unknown.
Growth trajectory is indeterminate, as no outlook data or revenue history is available for analysis. The company's future performance cannot be projected based on current inputs.
Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the absence of going-concern language in source documents. The company's dilution potential is low, and no adjustments have been applied to valuation metrics.
Recent events, including filings and transcripts, are not available in the provided data. No specific disclosures or developments can be cited at this time.
- Liquidity risk cannot be assessed due to missing balance-sheet data.
- Profitability and returns metrics are not available for comparison with industry benchmarks.
- Revenue concentration and geographic exposure are not disclosed.
- Growth trajectory and future performance cannot be projected.
- Dilution risk is low, with no near-term pressure identified.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$591.8k, +997,6% YoY; Operating income +11,4% YoY.
- ▍Revenue A$591.8k, +997,6% YoY
- ▍Operating income +11,4% YoY
- ▍Net income +11,4% YoY
- ▍Free cash flow +11,7% YoY
- ▍Net margin -1676.7%
Revenue A$53.9k, +186,1% YoY; Operating income −76,7% YoY.
- ▍Revenue A$53.9k, +186,1% YoY
- ▍Operating income −76,7% YoY
- ▍Net income −76,7% YoY
- ▍Free cash flow −80,2% YoY
- ▍Net margin -20775.2%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Racura Oncology Ltd Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Pete SmithExecutive Chairman of the Board
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 6.21xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.09xDerived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -35,172.7%Derived (calculated)
- Current assets (annual): USD 632.68KSEC XBRL filing
- Total assets (annual): USD 239.1MSEC XBRL filing
- Total liabilities (annual): USD 8.15MSEC XBRL filing
- Shareholders' equity (annual): USD -7.49MSEC XBRL filing
- Current liabilities (annual): USD 101.91KSEC XBRL filing
- Cash & equivalents (annual): USD 401.09KSEC XBRL filing
- Shareholders' equity (annual): USD -21.23KSEC XBRL filing